- Home
- SNGX vs KTTA Comparison
SNGX vs KTTA Comparison
Compare SNGX & KTTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNGX
- KTTA
- Stock Information
- Founded
- SNGX 1987
- KTTA 2020
- Country
- SNGX United States
- KTTA United States
- Employees
- SNGX N/A
- KTTA N/A
- Industry
- SNGX Biotechnology: Pharmaceutical Preparations
- KTTA Biotechnology: Pharmaceutical Preparations
- Sector
- SNGX Health Care
- KTTA Health Care
- Exchange
- SNGX Nasdaq
- KTTA Nasdaq
- Market Cap
- SNGX 4.3M
- KTTA 5.1M
- IPO Year
- SNGX 1987
- KTTA 2021
- Fundamental
- Price
- SNGX $2.78
- KTTA $0.70
- Analyst Decision
- SNGX Strong Buy
- KTTA
- Analyst Count
- SNGX 1
- KTTA 0
- Target Price
- SNGX $6.00
- KTTA N/A
- AVG Volume (30 Days)
- SNGX 22.2M
- KTTA 91.3K
- Earning Date
- SNGX 08-14-2025
- KTTA 08-14-2025
- Dividend Yield
- SNGX N/A
- KTTA N/A
- EPS Growth
- SNGX N/A
- KTTA N/A
- EPS
- SNGX N/A
- KTTA N/A
- Revenue
- SNGX N/A
- KTTA N/A
- Revenue This Year
- SNGX N/A
- KTTA N/A
- Revenue Next Year
- SNGX N/A
- KTTA N/A
- P/E Ratio
- SNGX N/A
- KTTA N/A
- Revenue Growth
- SNGX N/A
- KTTA N/A
- 52 Week Low
- SNGX $1.09
- KTTA $0.65
- 52 Week High
- SNGX $5.40
- KTTA $7.50
- Technical
- Relative Strength Index (RSI)
- SNGX 59.82
- KTTA 45.63
- Support Level
- SNGX $2.32
- KTTA $0.66
- Resistance Level
- SNGX $2.99
- KTTA $0.72
- Average True Range (ATR)
- SNGX 0.69
- KTTA 0.04
- MACD
- SNGX 0.02
- KTTA 0.00
- Stochastic Oscillator
- SNGX 38.10
- KTTA 39.04
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).
About KTTA Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module).